Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections.

Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units.

The company is headquartered in Cambridge, Massachusetts.